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ABSTRACT

Wright, Nathan Victor. M.S.B.M.E. Department of Biomedical, Industrial, and Human
Factors Engineering, Wright State University, 2016. Comparison of Vascular Pulsatility
in the Native Beating Heart versus Direct Mechanical Ventricular Actuation Support of
the Fibrillating Heart.

Most conventional cardiac assist devices today employ continuous flow blood pumps
to supplement function in the dysfunctional heart. Continuous flow pumps are
predominantly preferred to the original pulsatile pumps due to the smaller size (greater
implantability) and higher efficiency they achieve. However, interest in the impact of
vascular pulsatility on human health has arisen from the growing evidence of higher
complications with nonpulsatile devices compared to pulsatile devices. Direct cardiac
compression (DCC) offers a unique solution to the pulsatility issue through the
application of force directly to the heart’s surface. It is believed that employing the
existing pump architecture of the heart better produces natural pulsatility than blood
pumps in series with the heart. The purpose of this study was to determine if external
cardiac compression by direct mechanical ventricular actuation (DMVA), produces
arterial pulsatile quality to that of the naturally beating heart. This concept was tested
using DMVA, a non-blood contacting DCC device capable of actively augmenting
diastole, on an acute fibrillating model in nine large animals (seven canine and two
swine). Hearts, being fibrillated in order to eliminate the heart’s natural function to
generate pulsatile blood flow, were supported by the DMVA device. Progressive
iv

myocardial weakening and acute failure throughout the experiment resulted from
repeated cycles of fibrillation and defibrillation. Aortic pressures and flows were
recorded periodically in ten second captures. Conventional measures of pulsatility (pulse
pressure, energy equivalent pressure, surplus hemodynamic energy, frequency pulsatility
index) were computed from these captures for comparison of arterial pulsatility between
the naturally beating heart and the fibrillating heart supported by DMVA. Pulsatility in
the naturally beating heart was measured from both the healthy normal heart and the
weakened heart. Mean aortic flows and pressures were equivalent between DMVA
condition and unsupported weakened heart condition. The results suggests pulsatile
similarity between DMVA support for the fibrillating heart and the unsupported naturally
beating heart. No index of arterial pulsatility was significantly lower from DMVA
support heart compared to the unsupported beating heart at the same level of cardiac
output (p>0.05). DMVA proved able to restore arterial blood flow pulsatility in the
fibrillating heart compared to the naturally beating heart.
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I. INTRODUCTION
Heart disease is the leading cause of death in the United States in the twenty-first
century, responsible for twenty-five percent of all deaths according to the Centers for
Disease Control and Prevention [1]. Given the limitations inherent to drug therapies and
cardiac transplantation, cardiac assist devices have seen increasing prevalence in the past
few decades for their utility in unloading the heart. Though first generation assist devices
employed physiologic pulsatile blood pumps, nonpulsatile or continuous flow pumps
which use impellers to continuously circulate blood are now the standard. Their smaller
size, energy efficiency, and durability (fewer moving parts) allow for better
implantability compared to the bulkier, percutaneous pulsatile devices. However, interest
in physiologic pulsatile devices has been renewed because complications in nonpulsatile
devices have been seen over time (see Table 1 for a summary of the following
comparisons).

CONSEQUENCES OF NONPULSATILE CIRCULATION
BARORECEPTORS
The performance of vascular baroreceptors are linked to the pressure and flow
characteristics in blood circulation. Vascular baroreceptors participate in the regulation of
blood pressure by altering vascular tone. Renal baroreceptors, sensitive of pressure drops,
activate the renin-angiotensin cycle to contract or dilate vessels as needed for suitable
renal perfusion [2]. Baroreceptors are also sensitive to vascular pulsatility,
1

indicated by higher glomerular filtration rates with increased pulsatility and higher flow
rates. Mandelbaum and Burns demonstrated that arterial pressure elevates in nonpulsatile
perfusion compared to pulsatile perfusion at equivalent levels of cardiac outputs. When
canines on cardiopulmonary bypass (CPB) were subjected to similar mean flow rates for
both pulsatile and nonpulsatile perfusion, the arterial pressure increased significantly in
the nonpulsatile group [3]. Continuous flow devices must compensate for the absence of
pulsatility by increasing pump speeds, leading to many adverse hematological concerns
discussed in subsequent sections. Sympathetic nervous activity in the carotid sinus, which
is regulated by baroreception, has been observed to reduce during nonpulsatile
circulation, suggesting an element of electrical dysfunction [4-5].
HEMATOLOGY
Several studies have shown that nonpulsatile perfusion is associated with
gastrointestinal (GI) bleeding compared to pulsatile perfusion [6-11]. Increased bleeding,
particularly in the brain and GI tract, is likely the result of anticoagulation necessary for
any blood pump; however, the discrepancy in incidences of bleeding between
nonpulsatile and pulsatile devices suggests another mechanism involved. Pulsatility may
influence blood clotting pathways via endothelial release of von Willebrand factor. This
was recognized due to the higher observed incidence of acquired von Willebrand disease.
Unusually higher shear stresses in nonpulsatile pumps can result in the loss of high
molecular weight multimers of von Willebrand factors which are responsible for binding
collagen to platelets for clotting [6-7,10,12].
Arteriovenous malformations (AVM) tend to form in the GI tract because of
insufficient perfusion of intestinal mucosa during nonpulsatile circulation. Decreased
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pulse pressure and malperfusion cause mucosal ischemia and reconstruction of mucosal
vascular network. Shear-induced upregulation of vascular endothelial growth factor
(VEGF) may also be responsible for increased angiogenesis. The formation of these
AVM intensifies GI bleeding [10,13-14] since the new vessel walls are thinner and less
durable than the preexisting vessels. It also has been shown that incidences of hemolysis
are significant in patients with nonpulsatile cardiac support devices [15-16], mostly
occurring in proximity to the impeller.
RENAL FUNCTION
Kidney circulation and kidney metabolism has been found inferior for nonpulsatile
circulation. In canine experiments comparing pulsatile CPB to continuous flow CPB,
renal function decreased in the nonpulsatile group. This group experienced higher excess
lactate levels, higher renal arteriovenous lactate differences, and higher peripheral
vascular resistance [17]. Similar clinical studies, measuring the renal function in terms of
biomarkers, have confirmed adverse kidney response. One study of patients above the
age of seventy evaluated the effect of CPB flow on the renal function, and concluded that
nonpulsatile perfusion during was inferior to pulsatile perfusion. At three days postoperation, the nonpulsatile group had significantly higher levels of cystatin C and
creatinine (biomarkers of renal health) and higher blood urea nitrogen levels. Likewise,
the nonpulsatile group had significantly lower urine output and more incidences of acute
kidney injury [18]. Two meta-analyses have investigated large scale the comparisons of
continuous circulation’s effect on kidney function. The first meta-analysis compiled the
data of ten studies that included 477 patients on nonpulsatile CPB and 708 patients on
pulsatile CPB. These patients were considered for this meta-analysis because they met
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the following criteria: research was prospective in nature, trial on human subjects,
baseline demographics were recorded, and that outcome data included renal function
biomarkers. The second meta-analysis considered the data of nine studies, with 674 on
pulsatile CPB and 798 patients on nonpulsatile CPB. This second meta-analysis
investigated renal function biomarkers and renal malfunctions. Both meta-analyses
concluded that nonpulsatile perfusion during CPB was disadvantageous to pulsatile
perfusion for post-operative renal function based on significant differences in creatinine
clearances, serum lactate levels, serum creatinine and greater incidences of acute renal
insufficiency in nonpulsatile perfusion [19-20].
LYMPHATIC FLOW
Lymphatic formation and circulation were shown to diminish in the presence of
nonpulsatile arterial circulation, but were normal and similar to physiological levels in
the presence of artificially generated pulsatile circulation. This was first discovered in
experiments on rabbit ears. Continuous perfusion corresponded to a reduction in lymph
formation and circulation while pulsatile perfusion corresponded to lymph formation and
circulation [21]. With similar experiments on rabbit ears, it was also shown that
interstitial fluid movement is promoted by pulsatile perfusion. Edema in the interstitial
space increased, when the ears were subject to nonpulsatile arterial circulation. But
pulsatile perfusion caused immediate fluid movement in the interstitial space [22]. It has
been shown that reduction in arterial pulsatility suppresses the formation and flow of
cerebral spinal fluid (CSF) likewise. During nonpulsatile blood circulation, once
lymphatic or CSF flow has been diminished, pressure increases in interstitial space. The
pressure gradient between the interstitial space and the capillaries then decreases,
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reducing osmosis through the capillaries. High oncotic pressure may further increase the
interstitial fluid pressure. If the interstitial fluid pressure surpasses the pressure in the
capillaries, the capillaries may collapse [23].
NEUROLOGICAL
Neurologic recovery following cardiac arrest was shown to improve with pulsatile
resuscitation through direct cardiac compression compared to nonpulsatile CPB; canines
were arrested and then reperfused with either pulsatile biventricular cardiac massage or
nonpulsatile CPB and later evaluated for neurological recovery after the animals were
deceased. Nonpulsatile perfusion resulted in more severe loss of CA1 pyramidal neurons,
and higher incidences of ischemic changes in caudate nucleus and water shed regions of
the cerebral cortex [24]. In a similar study of canines on CPB, acute cell swelling and
early ischemic cell change were seen in the canines subject nonpulsatile perfusion but not
in the pulsatile group [23].
VASCULAR
In a study of patients on CPB that were high risk for cardiac surgery, microcirculation
deteriorated in the patients on nonpulsatile CPB compared to pulsatile CPB; O’Neil, et
al., found that a lower proportion of normally perfused micro-vessels occurred during
nonpulsatile CPB. They also found an increase in leukocyte activation in the
microcirculation from nonpulsatile circulation [25]. In left ventricular assist devices
(LVAD), nonpulsatile pumps are more likely to cause aortic insufficiency (AI) than
pulsatile pumps [26-28 44-46]. Higher blood flow velocities and shear stress of the
nonpulsatile circulation intensify the blood flow dynamics. The aortic medial layer
experiences thinning from the higher stresses because of a replacement of normal smooth
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muscle tissue with atrophic smooth muscle cells, resulting in aortic root dilation and AI
[28]. Commissural fusion, which was shown to be more common in nonpulsatile LVAD
than in pulsatile flow LVAD, could contribute to AI [29]. Hatano, et al., showed that
patients on nonpulsatile LVAD were at higher risk of aortic insufficiency than the [27].
Overall, strong evidence has shown the superiority of pulsatile circulation to
nonpulsatile circulation. A large-scale study, comparing pulsatile CPB to nonpulsatile
CPB, found significant risks from nonpulsatile circulation. Of 350 patients on CPB,
evenly distributed between pulsatile and nonpulsatile, total mortality, the number of
deaths attributed to post-perfusion low cardiac output, and the necessity of intra-aortic
balloon or drug circulation support were significantly higher in the nonpulsatile group
while the increase in hemolysis, postoperative bleeding complications, and blood cell
depletion were not associated with pulsatile group [30]. A summary of health issues
associated with nonpulsatile flow is shown in Table 1.
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Table 1 – Summary of issues associated with vascular blood flow non-pulsatility from
cardiac assist devices. While continuous flow devices offer greater implantability,
nonpulsatile devices have been associated with greater incidence of adverse health
outcomes compared to pulsatile devices.
Summary of Problems with Nonpulsatile Circulation
Area
Baroreceptors
Hematological
Clotting
Renal Function
Lymphatic
Immune
Dysfunction
Vascular
Dysfunction

Effect
-Sensitivity to nonpulsatile circulation (renin-angiotensin dysfunction)
-Acquired von Willebrand Syndrome (reduced clotting ability)
-AV Malformations (VEGF dysfunction promotes abnormal angiogenesis)
-Increased hemolysis
-Greater incidence of bleeding or thrombosis (anticoagulants or flow-based
platelet dysfunction)
-Altered renal blood flow regulation and low perfusion
-Decreased lymph flow, increased interstitial fluid retention
-Increased leukocyte activation and inflammation
-Greater evidence of infection
-Reduced microcirculatory perfusion and vascular bed patency
-Shear-based endothelial dysfunction
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DIRECT MECHANICAL VENTRICULAR ACTUATION
As discussed, most cardiac assist devices are blood pumps. However, direct cardiac
compression (DCC) devices, which augment pump function by directly applying force to
the surface of the heart, have been increasingly considered as alternative to blood pumps.
DCC devices have included cups, cuffs, and skeletal muscle (cardiomyoplasty) [31]. Our
lab has been working on a form of DCC called direct mechanical ventricular actuation
(DMVA), comprising a contoured polymer cup placed over the ventricles which is driven
by a percutaneous drive system. The cup has a hard outer housing and a flexible inner
diaphragm bonded together at the rim and apex (Figure 1). The drive system generates
support by inflating and deflating the sealed extradiaphragmatic space between the
housing and diaphragm, facilitating systole and diastole respectively. A continuous apical
vacuum prevents the heart from being ejected during support and maintains good contact
between the epicardium and diaphragm [32]. The significant difference between DMVA
and other DCC devices is the ability to augment diastolic function. Most DCC are merely
heart compression devices and depend on passive filling for diastolic function.
Though most cardiac assist devices require tedious and highly controlled procedures
for implantation and application, DMVA is advantageous for a resuscitative role due to
its rapid installation. The relative simplicity of providing surgical access to the heart
(which can be done by a general surgeon), without need for cannulation, allows for
documented installation times of less than five minutes in both animal [33-34] and
clinical [32, 35-36] studies. With respect to long-term device applications, DMVA has
considerable benefits to blood pump devices. Most notably is the lack of blood contact. In
order to prevent thrombosis from the blood pumps, anticoagulants must be provided for
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the duration of support, causing bleeding risks. The invasiveness of blood contact also
produces greater risk for infections compared to devices operating external to the heart.
DMVA is also naturally biventricular, which helps to balance output from both sides of
the heart.
DMVA has been shown to return cardiac hemodynamic output to near normal levels
in animal hearts following fibrillation from circulatory arrest [32-43]. Cardiac and
cerebral resuscitation are significantly improved by DMVA compared to closed-chest
compression [32], open-chest cardiac massage [33], and CPB [37-40]. In canine
comparisons between DMVA and CPB support for cardiac arrest, neurological recovery
was significantly better in the canines supported by DMVA based on levels of cerebral
oxygen consumption, loss of neurons, and ischemic changes [37, 40]. DMVA proved
applicable as bridge-to-transport in clinical trials, without inducing significant myocardial
trauma [35, 41]. In studies of canines supported by CPB or DMVA following coronary
artery bypass grafting, subjects supported by DMVA had better graft integrity with no
anastomotic disruption [42-43]. Cadaver kidney preservation has also been successfully
performed through DMVA use [44].
In addition to supplementing blood pumping ability, direct actuation of cardiac tissue
may provide additional benefits in preventing atrophy and unloading heart and
modulating cellular stretch signaling. Since DMVA makes use of existing cardiac
structure, it has been suggested that the cup may be able to generate the pulsatile flow
and pressure characteristics similar to those generated by the physiologically contracting
heart.

9

Figure 1. DMVA is a non-blood contacting form of direct cardiac compression. DMVA
consists of a polymer cup composed of a hard outer shell enclosing a flexible polymer
diaphragm. The ventricles are positioned against the diaphragm up to the AV groove. The
isolated space between the shell and diaphragm is expanded and retracted using a
pneumatic piston to augment both systolic contraction and diastolic relaxation. These
forces are translated to the ventricular surface after proper device attachment. Attachment
is achieved by a continuous low vacuum delivered via an apical port. This vacuum both
prevents expulsion of the heart during systolic compression and allows better contact
between the diaphragm and epicardium. Inflation of extradiaphragmatic space contracts
the ventricular myocardium introduce systolic function, and deflation of the space relaxes
the ventricular myocardium to introduce diastolic function.
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PURPOSE
The purpose of this study was to determine if external cardiac compression by DMVA
produces arterial flow and pressure pulsatile characteristics similar to the native beating
heart. This was assessed using an acute fibrillating heart model to evaluate pulsatility due
to DMVA support alone.
Hypothesis: DMVA support of the fibrillating heart restores arterial hemodynamic
pulsatility to that of the beating heart.
This thesis is accomplished by the following specific aims:
1. Determine if conventional measures of vascular pulsatility (pulse pressure, frequency
pulsatility index, energy equivalent pressure, surplus hemodynamic energy) are
equivalent between the non-beating DMVA-supported heart and the unsupported beating
heart.
2. Determine if differences in mean arterial pressures and flows affect pulsatility
comparisons between the non-beating DMVA-supported heart and the unsupported
beating heart.
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QUANTIFYING PULSATILITY
A major challenge to the research of pulsatility is inconsistency in defining or
quantifying pulsatile character. After over sixty years of investigating pulsatility, no
standard criteria or definition has been established for what qualifies pulsatile circulation
[45]. Much literature from the past has considered only extremes in the blood pressure as
the quality of pulsatility. This approach fails to recognize the hemodynamics quality of
the blood flow and inadequately disregards flow rate pulses. Pulsatile circulation is
polymorphic with a hemodynamic energy gradient; physiologic pulsatility is evidenced in
its flow patterns and hemodynamic energy levels [46]. Pulsatile flow is generated from
energy gradients, not pressure gradients. Continuous flow pumps, such as roller pumps,
have been modified to introduce an essence of pulsatility in their circulation based on a
pressure-defined pulsatility [47]. When such pseudo-pulsatile pump are implemented
into mechanical circulatory support and labeled as pulsatile, their conclusions might be
suspect because their flow characteristics are much different than physiologic pulsatility
[48-49]. Though the pseudo-pulsatile pumps generate flow with equivalent mean and
extreme pressures to physiologic flow, they generate significantly different flow patterns
and hemodynamic energy levels [46]. Research that disclaims the advantages of pulsatile
perfusion to nonpulsatile perfusion may be inadequate because their definition of
pulsatility ignores flow hemodynamics [48-49]. To legitimize research, pulsatility should
be quantified based on hemodynamic flow patterns and energy levels in addition to
pulses in pressure.

12

PULSE PRESSURE
Metrics of pulsatility have been based upon a number of factors including pressure,
flow velocity, flow harmonics, and hemodynamic energy levels in arterial flow. Pulse
pressure (PP), the most rudimentary measure, quantifies pulsatility as the difference
between systolic pressure (Psys) and diastolic pressure (Pdia) [50].
PP = Psys − Pdia

(1)

As defined by PP, blood flow becomes nonpulsatile when PP has been diminished;
mechanical circulatory support devices are considered nonpulsatile when PP is less than
15 mmHg, and pulsatile when PP is greater than 15mmHg [45, 51]. Safar, et al.,
investigated the relation between PP and end-stage renal disease and concluded that the
reduction of aortic-brachial PP amplification was a significant predictor of all-cause
mortality in patients with end-stage renal disease. They also found that carotid PP was a
better predictor of overall mortality than brachial PP [50]. Myers, et al., investigated the
correlation of PP to pump speed of continuous flow LVAD. They found that smaller PP
resulted in the inability of aortic valve to open normally, increasing risk of complications
[52]. PP is not the most efficient measure of blood flow pulsatility because it does not
recognize hemodynamic properties of the flow. LVAD or CPB can generate similar PPs
to that of the beating heart, but differ greatly from physiologic circulation in their flow
profiles and energy levels [46].
PULSATILITY INDEX
Pulsatility index (PI) quantifies pulsatile circulation based on variations in flow
velocities; it is the difference between maximum systolic velocity (Vsys) and minimum
diastolic velocity (Vdia) over the mean flow velocity (Vmean) in a vessel [53-54].
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PI =

Vsys −Vdia
Vmean

(2)

PI is applicable for the calculation of pulsatility in cerebral vessels, and is measured
based on transcranial Doppler. PI has been found to correlate with intracranial pressure
[55-56]. Soehle, et al., investigated the relationship between vital conditions including PI
to mortality and morbidity of patients who had subarachnoid hemorrhages. They only
concluded that higher PIs, or higher cerebral blood pulsatility, were predictive of negative
outcomes [57]. PI has not been found to compare pulsatile and nonpulsatile perfusion.
FREQUENCY PULSATILITY INDEX
Pulsatility can be quantified in terms of the frequency harmonics of the pulsatile blood
flow [58-60]. The heart’s pump function by nature generates cyclic frequency in the flow.
Every periodic curve can be transformed into a series of sine curves or harmonics on the
frequency domain (Figure 2). The flow frequency in arterial circulation is driven by the
beating heart, while continuous or nonpulsatile flow has no cyclic frequency. Pulsatility
based on flow frequency can be quantified as the frequency pulsatility index (PIfreq).
PIfreq is calculated by transforming the flow into its frequency spectrum with the Fast
Fourier transform (FFT) and analyzing the harmonic amplitudes. The equation is

PIfreq =

Σ(A2i )
A20

(3)

where Ai is the amplitude of each harmonic and A0 is the amplitude of mean flow. PIfreq
is dependent on wave frequency (heart beat or systolic duration) and flow magnitude.
PIfreq has been analyzed for optimization of end organ health, for comparison between
pulsatile and nonpulsatile cardiac support, and for relationship with vascular resistance
[58-61].
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A

B

Figure 2. (A) Example of aortic flow waveform. (B) Fourier transform of flow waveform.
The FFT is a set of sinusoid waves that model the flow on the frequency domain. PIfreq is
calculated from the harmonic amplitudes. The harmonics (A1-10) are squared and
summed, and divided by the square of the mean flow (A0).
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ENERGY EQUIVALENT PRESSURE
Because pulsatile circulation is dependent on energy gradients rather than pressure
gradients and pulsatile flow is quite different than continuous flow in levels of
hemodynamic energy, pulsatility has been quantified as an energy equivalent pressure
(EEP) which is the ratio between the hemodynamic energy and the flow volume during a
specific time period (the area under the hemodynamic power curve to the area under the
flow curve) [62-63].
EEP =

∫ flow∗pressure
∫ flow dt

dt

(4)

Intrinsic to fluid motion is the energy present in the blood flow. The pulsatile energy is
the excess energy in the pulsatile flow above what a continuous flow at the same mean
rate possesses; the quantity of pulsatile energy is the difference between EEP and mean
arterial pressure (MAP) [49]. Continuous flow, which has no pulsatile energy, has an
EEP equal to its MAP; surplus hemodynamic energy (SHE) is the difference between
EEP and MAP in energy per volume units. Total hemodynamic energy (THE) is the
conversion of EEP to energy per volume units [63].
SHE = 1332 ∗ (EEP − MAP) [ergs/cm3 ]

(5)

THE = 1332 ∗ EEP [ergs/cm3 ]

(6)

SHE and THE can be converted to the SI units of J/m3 by dividing by 10. The loss in
pulsatile energy by nonpulsatile circulation is observed by the decrease in the difference
between EEP and MAP. A pump’s ability to generate hemodynamic energy similar to
that the beating heart can be evidences by this difference. The normal human heart has a
ten percent difference between EEP and MAP [47]. In experimental studies, physiologic
pulsatile pumps generated a ten to twelve percent difference in experiments on pigs,
16

pseudo-pulsatile pumps (nonpulsatile pumps that are manipulated to generate a pulse
pressure) generated a three to five percent difference, and nonpulsatile pumps generated a
zero to one percent difference between EEP and MAP [64].
Even when CPB might employ pulsatile pumps, the energy in the blood flow can be
dissipated in the CPB system before reaching the patient’s body. Lim, et al., analyzed the
system settings and configuration of CPB and extra-corporeal life support (ECLS) to
maximize the human arterial pulsatility levels, in terms of EEP, SHE, and THE [46]. Lee,
et al., performed similar experiments on the configuration of the ECLS circuit to optimize
arterial pulsatility in terms of EEP, SHE, and THE [65]. Undar, et al., investigated the
pulsatility of CPB on neonatal pig hearts and found that physiologic pulsatile pumps
generate higher hemodynamic energy levels than other kinds of pumps [66]. Bartoli, et
al., compared arterial EEP of LVAD supported bovine hearts between pulsatile and
continuous flow pumps. EEP, SHE, and their percent difference were significantly lower
in the nonpulsatile devices compared to the pulsatile devices and compared to the native
heart. The volume-pressure relationship in the nonpulsatile group diminished, and the
opening aortic valve was restricted [67]. Travis, et al., compared the correlation of EEP to
vasculature impedance and compliance for pulsatile and nonpulsatile LVAD at high and
low support. Pulsatility, based on hemodynamic energy, decreased in nonpulsatile LVAD
group but was restored to baseline levels in pulsatile LVAD group. Their results showed
that vascular impedance immediately increased with nonpulsatile LVAD and decreased
with pulsatile LVAD, though this was not indicative of impedance for long term support
[63].
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POWER
Because metrics such as EEP and SHE quantify pulsatility essentially as a pressure,
attempts have been made to quantity pulsatile flow by power components [68-69]. The
hydraulic power from the left ventricle delivered through the blood flow to the systemic
circulation consists of a potential power derived from pressure, a minimal kinetic power,
and a negligible gravitational potential power. This pressure potential power is the
product of instantaneous aortic flow and pressure
𝑊̇ (𝑡) = 𝑝(𝑡) ∗ 𝑓(𝑡)

(7)

where 𝑊̇ (t) is the potential power, and p(t) and f(t) are the Fourier transforms of the
instantaneous aortic pressure and flow waves respectively. When the flow and pressure
transforms are multiplied together and rearranged, the active power can be equated as
1
𝑊̇𝑎𝑐𝑡 = 𝑊̇𝑠𝑑𝑡𝑦 + 𝑊̇𝑝𝑢𝑙𝑠 = 𝑃𝑜 𝑄𝑜 + 2 ∑𝑁
𝑛=1 𝑃𝑛 𝑄𝑛 cos(𝜙𝑛 − 𝜃𝑛 )

(8)

Where 𝑃𝑜 is mean pressure, 𝑄𝑜 is mean flow, 𝑃𝑛 is the nth pressure harmonic, 𝑄𝑛 is the nth
flow harmonic, and 𝜙𝑛 − 𝜃𝑛 is the phase difference between flow and pressure [69]. The
active power has a steady flow power (𝑊̇𝑠𝑑𝑡𝑦 ), which is the minimum power required to
deliver blood flow to systemic circulation, and a pulsatile power (𝑊̇𝑝𝑢𝑙𝑠 ), which is the
power delivered into the pulses and not contributing to forward flow. The pulsatility
portion of active power provides a metric of pulsatility. Studies have been performed to
link the pulsatility components of power to arterial resistance and elasticity [69]. Both
pressure and flow are accounted for in this metric of power units, while EEP and SHE
cancel out the flow to be in pressure units.
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SHEAR STRESS
Consequent of the blood flow is the shearing of endothelium which actively regulates
many physiological blood vessel responses. Increase in shear stress can stimulate
arteriogenesis, formation of new arteries. The rise in shear stress from the increase of the
continuous flow rate to maintain pressure levels can promote endothelial cell migration,
and thus arteriogenesis [70]. Assistance in vascular defense is also a role of shear stress.
Nitric oxide (NO), an important protective molecule in the vasculature, is produced in a
process called endothelial nitric oxide synthase (eNOS). The increase in shear stress
stimulates eNOS activity [71-72]. Shear stress is a function of shear rate, and shear rate is
a function of flow rate. Normal arterial values of shear stress range between ten and forty
dyne/cm2. But because arterial flow is pulsatile and due to meandering of vessels, the
flow is at times disturbed, and the shear stress can become negative or exceed normal
values. Likewise, non-physiologic conditions can raise the levels of shear stress [70].
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II. METHODS
The Wright State University Lab Animal Care and Use Committee approved the
experimental protocol, and all animals were treated in compliance with the Guide for the
Care and Use of Laboratory Animals, published by the National Institutes of Health,
revised 1996.
SURGICAL PROTOCOL AND EXPERIMENTAL TIMELINE
This study consisted of nine large animal models, seven canines and two swine. Both
canines and swine were considered to represent various cardiac sizes. Swine hearts
represent larger human hearts, and canine hearts represent smaller human hearts. The
subjects were pre-anesthetized with Telazol (6 mg/kg), Xylazine (3 mg/kg), and Atropine
(0.02 mg/kg). After which, the subjects were treated with tracheal intubation and
mechanical ventilation. Drug infusion was administered by vascular access through
bilateral femoral cutdowns. Anesthesia was maintained with 1-2% isoflurane, and arterial
pressure was regulated with phenylephrine. Median sternotomy and pericardiotomy were
performed to fit the cup to the animal hearts. The subjects were monitored for left
ventricular, aortic, and central venous pressures with Spectramed P23xl pressure
transducers. A median sternotomy and a pericardiotomy were performed on the subjects.
A COfidence ultrasound flow probe with a TS420 perivascular module was inserted
about the ascending aorta for monitoring cardiac output. A computer acquisition system
monitored hemodynamics, pulse oximetry, end-tidal dioxide, and rectal temperature.
DMVA drive systems were instrumented to measure pulsatile and continuous vacuum
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pneumatic pressure and pulsatile flow. The schematic of instrumentation setup is in
Figure 3.
The experimental timeline began with the pre-experimental condition. The preexperiment condition provided a baseline to measure the pulsatility of the healthy beating
heart. The experiment consisted of ventricular fibrillation, a period of DMVA support,
defibrillation, and a period of beating without support. Post-sternotomy baseline data was
recorded. To induce ventricular fibrillation (V-FIB), a 9-volt battery shocked the
ventricles through the epicardium. V-FIB continued for a five minute period, after which
DMVA support was given for fifteen minutes. The hearts were then defibrillated after the
period of DMVA support. If defibrillation failed to restore normal cardiac rhythm or if
severe failure was present (cardiac output ≤ 60% baseline), DMVA support was
reapplied for an additional fifteen minutes; but if defibrillation successfully restored the
heart to its normal cardiac rhythms, the heart would remain unsupported for fifteen
minutes of recovery. After the recovery or supported failure, the heart was again
fibrillated and the cycle was repeated. This cycle was repeated for approximately two
hours (Figure 4).
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Figure 3. Schematic of experimental setup for data collection. Data collection
instrumentation included aortic flow meter, aortic pressure transducer, pneumatic
pressure transducer and flow meter, and drive system. Animals were instrumented for
flow and pressure readings at the ascending aorta.
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Figure 4. Experimental timeline used for this study. After taking physiologic baseline
measurements (following medial sternotomy and instrumenting animal for pressure and
flow readings), ventricular fibrillation was generated using a direct current shock to the
heart surface. After five minutes of fibrillation without support, DMVA was applied to
the fibrillating heart. Following the fifteen minute period of DMVA support, the cup was
removed and the heart was defibrillated. If successful, the beating hearts were commonly
in failure. After a DMVA support period for the failing heart, the cycle was started again.
In this way different levels of cardiac health were assessed as the animal became more
dysfunctional with repeated cycles.
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Ascending aorta pressure and flow data was recorded throughout the experiment over
several hundred ten-second captures at 800 Hz. For comparison between DMVA and the
naturally beating heart, the data was categorized into the experimental conditions. After
which, the data captures of aortic flow and pressure were analyzed for calculation of
arterial pulsatility. Captures from support during failure, captures without pressure and
flow data, and captures during periods of inadequate DMVA support were excluded. (For
the rest of this paper, “support” refers exclusively to support during fibrillation.)
Experimental conditions were divided into (1) the pre-experiment beating heart, (2)
DMVA support during fibrillation at normal physiologic cardiac output (output greater
than 60% of the baseline output), and (3) the unsupported beating heart following
defibrillation at normal physiologic levels. The conditions of DMVA support and postarrest beating heart had equivalent levels of mean arterial pressure and aortic flow,
providing similar conditions of the pulsatility comparison. Baseline arterial flow and
pressure was higher than post-arrest and DMVA supported arterial flow and pressure.
Table 2 describes experimental conditions.
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Table 2. This experiment compared pulsatility as generated by DMVA during fibrillation
to the pulsatility generated from the naturally beating heart. Experimental conditions
were classified as DMVA support and beating heart pre-experiment or beating heart postarrest. Mean aortic flow and MAP was not significant between supported heart and postarrest beating heart. Arterial pulsatility from DMVA could be compared to the beating
heart at similar conditions and to the baseline healthy beating heart.
Experimental
Condition

Sample
Size

CO
(L/min)

MAP
(mmHg)

Pre-Experiment
Beating Heart

35

3.08
± 0.06

94.20
± 4.03

DMVA Support for
Fibrillating Heart

47

2.71
± 0.05*

77.33
± 4.24*

Post-Arrest
Beating Heart

87

2.70
± .05*

83.60
± 3.63*

Values expressed as Mean ± SEM; * p<0.05 vs Baseline
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Description

Baseline post-sternotomy condition of
unsupported heart before experiment
Condition during experiment when heart was
fibrillating and supported by DMVA and cardiac
output was at normal levels (CO > 60% baseline
CO)
Condition during experiment when heart was
beating without support following defibrillation
(CO > 60% baseline CO)

ANALYTIC MEASURES
Pulse pressure (PP), as defined in Equation 1, accounts for variance between systolic
and diastolic pressure. In the data captures, instantaneous pressure waveforms were
recorded, from which systole and diastole were measured. Pulse pressure was calculated
from these pressure wave forms as the difference between the systolic pressure and the
diastolic pressure. PP was calculated for comparison between the supported heart and the
beating heart from 131 data captures. Traces with poor signal resolution were excluded.
The frequency pulsatility index (PIfreq), quantifies pulsatility based on the frequency
harmonics in the blood flow. Equation 3 defines PIfreq as the ratio of the sum of flow
harmonics squared to the mean flow squared. This index requires flow to be transformed
to frequency spectrum by FFT to measure the harmonic amplitudes. The flow wave forms
from 169 data captures was transformed by FFT to the frequency spectrum from which
PIfreq was calculated.
Based on hemodynamic energy, pulsatility is quantified as energy equivalent pressure
(EEP) and total hemodynamic energy (THE) and accounts for both pressure and flow
qualities in the blood flow. This measures hemodynamic energy in units of pressure and
energy per volume and is defined in Equations 4 and 6 as the amount of hemodynamic
energy per flow volume for a given period. Surplus hemodynamic energy (SHE), the
difference between EEP and MAP in terms of energy per volume, is defined in Equation
5. EEP, SHE, and THE were calculated from the flow and pressure wave forms from 169
captures during the experiment. To compare pulsatile energy when arterial pressure
differs among conditions, the ratio of EEP to MAP was calculated for relative pulsatility.
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EEP already calculates the hemodynamic energy in its numerator, but divides the
hemodynamic energy by the flow volume. EEP, therefore, cancels the flow out of its
index and remains only as a pressure. A power term could be calculated through dividing
the hemodynamic energy by the time period of the capture.
𝑃𝑜𝑤𝐼𝑑𝑥 =

∫ (𝑓𝑙𝑜𝑤∗𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒)𝑑𝑡
𝑡𝑖𝑚𝑒

(9)

This power index would have terms of pressure and flow and account for both the flow
and pressure qualities of pulsatile flow. This metric was calculated from 169 data
captures for comparison of DMVA to beating heart. Power index calculation was
converted to watts.
One of the effects of the blood flow is the shearing of endothelium. Instantaneous
aortic flow was recorded throughout the entire experiment, from which maximum shear
stress was approximated for each capture during baseline flow and during each
experimental condition. Shear rate for Poiseuille or laminar flow is defined by Equation 7
as a function of flow rate, and shear stress is defined by Equation 8 as function of shear
rate [73].

𝛾̇ =

32𝑄
𝜋𝐷3

𝜏 = 𝜇𝛾̇

(10)
(11)

In Equations 7 and 8, Q is the maximum flow rate for each capture, D is the inner
diameter of the vessel, and 𝜇 is the dynamic viscosity of blood. The pulsatile flow cannot
be assumed as purely laminar. But approximation of shear stress with Equation 8
provides a proportional comparison of shear stress from DMVA compared to beating
heart. In this study, the internal diameter of the ascending aorta in canines was
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approximated to 1.5 cm [74]. Dynamic viscosity was approximated with the dynamic
viscosity of human blood at 37°C to 0.0032 N*s/m2 [75]. Maximum shear stress was
calculated from about flow data captures from the canines.
Based on all these metrics, arterial pulsatility was compared between DMVA support
for fibrillation and the naturally beating heart. Student’s t-tests were performed between
experimental conditions. P-values below 0.05 indicated index significance between
conditions. These tests determined if pulsatility was restored by DMVA to that of the
naturally beating heart.
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Table 3. Metrics of Pulsatility. Each of these measures were calculated as a means to
quantify pulsatility. Pulsatility was compared between supported heart and beating heart
based on these measures.
Calculation

Equation

Pulse Pressure
Frequency Pulsatility
Index
Energy Equivalent
Pressure

PP = Psys - Pdia

Σ(𝐴2𝑖 )
=
𝐴20

[dimensionless]

∫ 𝑓𝑙𝑜𝑤 ∗ 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑑𝑡
∫ 𝑓𝑙𝑜𝑤 𝑑𝑡

[mmHg]

𝑃𝐼𝑓𝑟𝑒𝑞
𝐸𝐸𝑃 =

[mmHg]

Surplus
Hemodynamic
Energy

𝑆𝐻𝐸 = 𝐸𝐸𝑃 − 𝑀𝐴𝑃

[mmHg]

𝑆𝐻𝐸 = 1332 ∗ (𝐸𝐸𝑃 − 𝑀𝐴𝑃)

[erg/cm3]

Total Hemodynamic
Energy

𝑇𝐻𝐸 = 1332 ∗ 𝐸𝐸𝑃

[erg/cm3]

Power Index

𝑃𝑜𝑤𝐼𝑑𝑥 = 0.0022

Shear Stress

𝜏 = 𝜇𝛾̇
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∫ (𝑓 ∗ 𝑝)𝑑𝑡
𝑡𝑖𝑚𝑒

[m3/s*Pa or W]
[dyne/cm2]

III. RESULTS
AIM I: METRICS OF PULSATILITY
In execution of the first aim of this experiment, the conventional measures of pulsatile
quantification were performed for each experimental condition on all the flow and
pressure data captures. Statistical analysis was performed on each pulsatility metric for
comparison of arterial pulsatility between DMVA support and the unsupported beating
heart. Not all animals produced all experimental conditions for comparison between
beating and fibrillating supported heart. The following results are shown as mean ±
standard error.
PULSE PRESSURE
PP results from arterial blood flow were as follows: 68.95 ± 4.79 mmHg for baseline
beating heart, 70.57 ± 4.25 mmHg for DMVA support, and 39.71 ± 3.44 mmHg for
unsupported beating heart post-arrest. PP was significantly higher from DMVA support
compared to beating heart at the same cardiac output but had equivalent PP to baseline
healthy heart (Figure 5). Systolic pressure was found to be higher for fibrillation support
than for the beating the heart while diastolic pressure remained relatively constant
between supported and beating heart. The rise in PP of the supported heart was thus
caused by the rise in systolic pressure. When considering the animals individually, PP in
every animal was either not significant between supported and beating hearts, or higher in
the supported heart.
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Figure 5. Comparison of pulse pressure (mean and standard error) between the fibrillating
supported heart and the beating heart. PP was significantly higher during fibrillation
support than PP for beating heart at the same cardiac output. The beating heart was
progressively weakening, and the dysfunctional myocardium was unable to maintain
pulse pressure compared to DMVA support. Due to mechanisms of DMVA compression,
the systolic portion of the pressure wave was larger from the supported heart than from
the beating heart. DMVA’s PP was equivalent to the pre-experiment PP.
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FREQUENCY PULSATILITY INDEX
PIfreq results from arterial blood flow were as follows: 0.72 ± 0.05 for baseline beating
heart, 0.82 ± 0.04 for DMVA support, and 0.68 ± 0.04 for unsupported beating heart
post-arrest. Based on the frequency harmonics, DMVA’s PIfreq was significantly higher
than PIfreq of the post-arrest beating heart (Figure 6). Compared to the pre-experiment
beating heart, DMVA had no significance in terms of frequency harmonics. When
considering the animals individually, PIfreq had no significant differences between beating
heart and fibrillating heart in most cases. When PIfreq was significantly different, it was
higher in the fibrillating heart than in the beating heart.
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Figure 6. Comparison of PIfreq (mean and standard error) between supported heart and
beating heart. PIfreq was significantly higher support compared to the beating heart at the
same outputs. PIfreq was dependent on wave frequency and mean flow volume. Because
of myocardial dysfunction, the post-arrest beating heart may have experienced
inconsistency in flow wave frequency though flow was maintained, causing this measure
of pulsatility to be dropped for beating heart compared to supported heart.
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ENERGY EQUIVALENT PRESSURE
EEP results from arterial blood flow were as follows: 112.35 ± 4.21 mmHg for
baseline beating heart, 96.23 ± 4.43 mmHg for DMVA support, and 96.18 ± 3.79 mmHg
for unsupported beating heart post-arrest. According to the data of all animals combined,
EEP levels were not significantly different between the beating heart and the supported
fibrillating heart at the same cardiac output. EEP significantly decreased from preexperiment condition to DMVA and post-arrest beating heart conditions because flow
and pressure were at lower levels (Figure 7). These results were represented when
considering the animals individually. EEP was similar between the post-arrest beating
heart and the supported heart in almost all cases. Total hemodynamic energy results were
identical to EEP results because THE is the energy per volume conversion of EEP. Thus,
THE was not significant between the native beating heart and the fibrillating supported
heart.
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Figure 7. Comparison of EEP (mean and standard error) between supported and beating
heart at each experimental condition. EEP was not significant between beating heart and
supported heart at same output level. EEP dropped significantly as output level dropped.
Application of DMVA for the fibrillating heart restored hemodynamic energy to that of a
beating heart, relative to flow. However, EEP or hemodynamic energy was lower in
DMVA support than pre-experiment baseline because flow and pressure were lower
during DMVA support.
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Though EEP is a function of flow and pressure, EEP was plotted versus both to see
their effect on EEP (Figure 8). EEP appeared to grow fairly proportionally to mean aortic
flow. This relationship was dependent upon animal, however. The rate of EEP growth
with respect to flow varied among animals causing the fanning of data in the plot of EEP
versus flow. EEP had a strong linear relationship with MAP (R2 = 0.8), independent of
animal. Because the slope was less than 1.0, the change in MAP was greater than the
change in EEP between two captures; the difference between EEP and MAP decreased as
arterial blood pressure increases. These relationships did not appear to be affected by
whether the heart was beating on its own or the fibrillating heart was being supported by
the cup (Figure 9).
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Figure 8. Comparison of EEP to aortic flow (A) and to MAP (B). EEP seemed to increase
with aortic flow, when considering the data as a whole. But for animals individually,
there appeared to be a more linear relationship between EEP and flow. The rate of change
between EEP and flow varied in each animal causing the fanning of the data. There was a
strong linear relationship between EEP and mean arterial pressure (R2 = 0.80).
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Figure 9. Comparison between beating heart and supported heart of EEP to aortic flow
relationship (A) and of EEP to MAP relationship (B). Neither relationship seemed to be
affected by whether or not the heart was naturally beating or was supported during
fibrillation.
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Because EEP was proportionally dependent on MAP which varied among
experimental conditions and animals, and because the presence of pulsatility was
quantified in the difference between EEP and MAP, the ratio between EEP and MAP
provided an effective measure of pulsatility relative to pressure. The EEP to MAP ratio
results from arterial blood flow were as follows: 1.22 ± 0.02 for baseline beating heart,
1.26 ± 0.02 for DMVA support, and 1.16 ± 0.02 for unsupported beating heart postarrest. According to the data of all the animals combined, the EEP to MAP ratio was
significantly higher from DMVA support compared to post-arrest beating heart, but the
EEP to MAP ratio had no significance between DMVA support and pre-experiment
beating heart (Figure 10). DMVA restored hemodynamic energy relative to mean
pressure in the fibrillating heart to that of the naturally beating heart.
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Figure 12. Comparison of EEP/MAP to experimental conditions. EEP/MAP had no
significance between the supported heart and the pre-experiment beating heart. DMVA
had a higher EEP/MAP ratio than beating heart at same cardiac output. Though
hemodynamic energy relative to flow was similar between the two conditions, DMVA
offered higher hemodynamic energy relative to mean pressure than the beating heart.
This may have been due to some myocardial dysfunction from repeated fibrillation and
defibrillation.
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SURPLUS HEMODYNAMIC ENERGY
Surplus hemodynamic energy, the difference between EEP and MAP in terms of
energy per volume, quantifies the pulsatile energy present in pulsatile circulation. SHE
results from arterial blood flow were as follows: 18.15 ± 1.09 mmHg for baseline beating
heart, 18.94 ± 1.15 mmHg for DMVA support, and 12.59 ± 0.98 mmHg for unsupported
beating heart post-arrest. According to the data of all animals combined, SHE was
significantly higher for fibrillation support than for the naturally beating heart at the same
cardiac output (Figure 11). When compared to pre-experiment beating heart, SHE had no
significant difference. For the animals individually, SHE was not significant between
beating heart and fibrillating supported heart in most cases. SHE also had mostly no
significant between the pre-experiment heart and DMVA support. In cases of
significance, SHE was higher for support. DMVA support during fibrillation restored
pulsatility in terms of SHE to that of the naturally beating heart.
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Figure 11. Comparison of SHE (Mean and standard error) between supported heart and
beating heart. SHE was larger for supported heart compared to post-arrest beating heart at
the same cardiac output. DMVA had no significance in SHE with pre-experiment beating
heart. Significance may be due to a translation of energy to pulsatile form from cup
mechanics. Pulsatility in terms of SHE was restored by DMVA support of the fibrillating
heart to that of the naturally beating heart at similar flows.
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POWER INDEX
PowIdx, a measure for the amount of hemodynamic energy in the flow over the time
of the data capture, was calculated from flow and pressure data. PowIdx results from
arterial blood flow were as follows: 0.73 ± 0.03 W for baseline beating heart, 0.53 ± 0.03
W for DMVA support, and 0.53 ± 0.3 W for unsupported beating heart post-arrest.
According to the data of all animals combined, DMVA had no significance in terms of
PowIdx with the unsupported beating heart at the same cardiac output level. Though
DMVA had equivalent PowIdx as the beating heart at the same output level, DMVA had
a significantly lower PowIdx than the pre-experiment beating heart (Figure 12).
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Figure 12. Comparison of PowIdx (Mean and standard error) between supported heart
and beating heart. PowIdx was equivalent between supported heart compared and postarrest beating heart at the same cardiac output. DMVA’s PowIdx was significantly lower
than PowIdx of pre-experiment beating heart. Significance is because the pre-experiment
condition was at higher cardiac output, and higher hemodynamic energy levels. When
DMVA generated normal output levels, its PowIdx was equivalent to the beating heart at
the same output levels.
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SHEAR STRESS
Maximum endothelial shear stress results from arterial blood flow were as follows:
19.38 ± 0.91 dyne/cm2 for baseline beating heart, 22.21 ± 0.78 dyne/cm2 for DMVA
support, and 18.17 ± 0.72 dyne/cm2 for unsupported beating heart post-arrest. When the
heart was in fibrillation and supported by DMVA, levels of maximum endothelial shear
stress in the ascending aorta did not decrease compared to when the heart was naturally
beating (Figure 13). According to the data of all the animals combined, the maximum
shear stress was significantly higher from DMVA compared to the post-arrest beating
heart. Maximum shear stresses from DMVA were also significantly higher than those
from the pre-experiment beating heart.
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Figure 13. Comparison of endothelial shear stress (mean and standard error) in the
ascending aorta between beating and supported heart. Shear stress was significantly
higher for the supported heart than for the beating heart at both baseline condition and
post-arrest condition. Maximum shear stress decreased in beating heart from baseline to
post-arrest because flow rate had dropped.
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AIM II: EFFECTS OF AORTIC FLOW AND PRESSURE
In execution of the second aim, each metric of pulsatility was compared to mean aortic
flow and to mean aortic pressure to evaluate how those metrics were. MAP appeared to
have a positive correlation with flow rate (Figure 14). This relationship varied from
animal to animal, causing the data as a whole to be scattered; but for individual animals,
the correlation between pressure and flow was strong for a majority of animals (R2>0.5).
This relationship was not affected by whether or not the heart was beating or supported
during fibrillation (Figure 14.B). The association between pressure and flow was
important for analyzing pulsatility of this experiment because flow and pressure varied
among animals.
When comparing PP to either aortic flow or MAP, PP showed no apparent
relationship with either (Figure 15). These plots show that PP from the supported heart
was generally higher than PP from the beating heart. It was previously shown that PP was
significantly higher in the supported heart than in the beating heart at the same cardiac
output. Though pressure and flow level did not seem to affect PP, DMVA support did
generate higher PP than the beating heart. And this was shown to be the result of higher
relative systoles in the supported heart from the cup mechanism.
PIfreq, a function of flow frequency harmonics, seemed to rise as flow and pressure
drop (Figure 16). In the beating heart pressure and flow have little effect on PIfreq.
However, when the heart is supported, PIfreq seems to increase when both pressure and
flow decrease.
When comparing SHE to aortic flow and MAP, SHE seemed to decrease somewhat as
both increased, but with no strong correlation (Figure 17). This relationship did not seem
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to be affected by whether the heart was naturally beating or was being supported during
fibrillation.
Maximum shear stress, a function of maximum flow rate, had strong correlation with
cardiac output or mean aortic flow (Figure 18). In most animals, the coefficient of
determination (R2) between maximum shear stress and mean aortic flow was greater than
0.7. The comparison of maximum shear stress to MAP showed less correlation. Based on
these plots, shear stress did not seem to be affected by whether or not the flow was
generated by DMVA or by the beating heart.
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Figure 14. Comparison between MAP and aortic flow in all animals (A) and based on
flow generation (B). MAP appeared to increase as flow rate increased. In the majority of
animals, there was a fairly linear relationship between MAP and flow (R2 > 0.5). This
relationship was dependent on animal; the slope varies from animal to animal causing the
data as a whole to fan. The correlation between pressure and flow was not affected by
whether the flow is generated by the beating heart or by DMVA support of the fibrillating
heart. Because pressure and flow varied among animals, this relationship may have been
important for the pulsatile metrics.
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Figure 15. Comparison of PP to aortic flow (A) and mean arterial pressure (B). PP had no
apparent correlation to pressure or to flow. PP seemed to be higher in the supported heart
than in beating in both these plots. As already shown at the same output, PP was
significantly higher in the supported heart than in the beating heart. PP was not
apparently affected by magnitude of flow or pressure but was dependent upon source of
flow, whether from beating heart or DMVA supported heart.
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Figure 16. Comparison of PIfreq to aortic flow (A) and pressure (B). PIfreq seemed to
increase as both pressure and flow decreasd for the supported heart but not for the beating
heart. Because PIfreq quantifies pulsatility as the amount of wave frequency over the flow
magnitude, DMVA maintains wave frequency at lower volumes causing this index to
increase at lower outputs.
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Figure 17. Comparison of SHE to aortic flow (A) and to MAP (B). SHE seemed to
decrease as both increase but without strong correlation. SHE is the difference between
EEP and MAP. EEP and MAP were already shown to be linearly related, with MAP
growing faster than EEP. The decrease in MAP was faster than the decrease in EEP at the
lower flows and pressures, causing the difference between them to rise at the lower flows
and pressures; thus, SHE increased as MAP decreases. SHE’s relationship with pressure
and flow did not seem to be affected by whether or not the flow was generated by the
beating heart or by DMVA.
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Figure 18. Comparison of maximum aortic endothelial shear stress to aortic flow (A) and
to MAP (B). Maximum shear stress had strong linear relationship with aortic flow
(R2>0.7 in most animals). As mean flow rate in pulsatile flow increased, the maximum
flow rate would intuitively increase. Because shear stress is a function of flow rate,
maximum shear stress increased with flow rate. Shear stress had less correlation with
MAP, but did seem to increase with the rise in MAP. Shear stress did not seem to be
affected by whether the flow was generated by the beating heart or by DMVA.
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IV. DISCUSSSION
Given the lack of a standard measure for pulsatility, pulsatile quantification has been
somewhat inconsistent across the literature, though EEP seems to be the most represented
index in current literature. All of the measures included in this study derive their
quantification of pulsatility from flows and or pressure waveforms. Though both canine
and swine models were used, physiologic differences between canines and swine do not
confound these results since the comparison are normalized to each animal specifically.
Likewise, having both species provided representation of larger and smaller hearts.
Pulsatility could be directly compared between DMVA and the beating heart because
mean flows were normalized between subjects with minimal significance in aortic flows
and pressures.
Pulse pressure is the most basic method to quantify pulsatility, only representing the
extremes of the pressure signal. DMVA appeared to produce significantly higher pulse
pressures than the naturally beating heart at the same cardiac output. This increase was
largely due to significant increases in systolic pressure observed during DMVA support
while diastolic pressures remained relatively consistent. The rise in systolic pressure may
have been due to the mechanisms of the cup air pressure. Nonpulsatile flow pumps can be
manipulated to generate pulse pressures by varying pump impeller speed throughout the
cardiac cycle. However, the flow dynamics from these pumps differ from those of
physiologic pulsatile flow.
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Frequency analysis provides a measure of pulsatility based on the properties of the
Fourier transform. The Fourier transform fits a series of sinusoids in the frequencydomain plot from the flow data. A continuous flow signal shows up simply as the DC
component in a frequency-domain plot since no sinusoid can be fitted to a flat line.
Introducing pulsatility or flow frequency into the flow signal produces greater amplitudes
(harmonics) of the non-DC frequency values. Given this relationship, pulsatility can
reasonably be measured with the PIfreq which quantifies pulsatility as ratio of cycle
frequency to flow magnitude. Continuous flow has a PIfreq of zero because it lacks flow
frequency and has zero harmonics in its Fourier transform. The higher PIfreq from DMVA
support compared to the post-arrest beating heart can be explained by possible loss of
flow wave frequency when the heart was in failure. The dysfunctional myocardium could
alter the consistency of wave frequency or the numerator of this term at this condition
dropping its PIfreq below that of the supported heart. DMVA restored pulsatility in terms
of frequency harmonics to that of the pre-experiment beating heart.
Pulse pressure has been largely replaced by EEP to measure pulsatility because EEP
accounts for both pressure and flow and accounts for the entirety (integration) of both
signals rather than just the extremes. EEP is a measure of the total hemodynamic energy
per volume of blood flow in pressure terms. The difference between EEP and MAP
(SHE) provides a measure of pulsatility energy. There was no significant differences in
the EEP values between the supported heart and the beating hearts at the same cardiac
output. However, EEP from DMVA was lower than the EEP of the pre-experiment state
which was hyper-dynamic and possessing more energy per volume. SHE from DMVA
support was equivalent to the SHE of the pre-experiment beating heart, and was
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significantly higher than the SHE of the post-arrest beating heart at the same cardiac
output. Though DMVA was at the same energy per volume level (EEP) as the post-arrest
beating heart, this energy was translated into a pulsatile form since SHE was higher for
DMVA. Normalizing EEP relative to MAP provided the comparison of pulsatile energy
between flows at different mean pressures. A nonpulsatile flow has an EEP/MAP ratio
equal to 1.0; EEP/MAP of healthy human hearts was found to be about 1.1 [47]. The
average EEP/MAP from these animals was about 1.2. This ratio had no significant
difference between DMVA support and the pre-experiment beating heart.
The current methods to quantify pulsatility are not without concern, however.
Pulsatility in the blood is an effect that is present in both the pressure and flow dynamics.
Pulse pressure quantifies the pulsatility essentially as a pressure. And though EEP (along
with SHE) quantifies pulsatility based on hemodynamic energy, it characterizes
pulsatility ultimately as a pressure. To quantify pulsatile flow as a pressure fails
essentially disregards its flow dynamics. PIfreq quantifies pulsatility as a ratio of wave
frequency to flow volume; but this flow is dimensionless. Pulsatility, which has a
physical presence in pressure and flow, cannot validly be measured without dimensions.
Power analysis might more suitably quantify pulsatility because power is the product of
flow and pressure. Pulsatility studies using hemodynamic power as a metric are not
prevalent but have been attempted.
Relevant to pulsatile flow is the shear stresses from the flow to the endothelium.
Endothelial signaling is often impaired via altered stress profiles during mechanical
circulatory support. Continuous flow at the same mean rate as pulsatile flow would
decrease the maximum shear stress levels by over fifty percent of the maximum shearing
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of pulsatile flow. When continuous flow is increased for pressure regulation, maximum
shear stress could be at abnormal levels. Altered shear stresses in continuous flow
systems result in dysfunctional endothelial signaling (such as changes in reactive oxygen
and nitrogen species and abnormal angiogenesis). While the analysis in this study was
limited by assumptions of laminar flow, constant viscosity, and vessel diameter, the
results should be considered proportional in comparing continuous and pulsatile flow
systems with the similar flows. The pulsatile system is able to maintain transient shear
values far above a continuous system which may facilitate abnormal endothelial
signaling. Normal human values of arterial shear stress range between 10 and 40
dyne/cm2 [68]. In our animal tests, aortic maximum shear stresses were close to 20
dyne/cm2 for the beating heart and DMVA support.
Also of interest is the impact of mean aortic flow and pressures to the pulsatile
indices. Correlations between aortic flow and pressure were observed. When plotted
against each other, MAP appeared linearly proportional to flow from animal to animal
(R2 > 0.5 in most animals). The link between flow and pressure might have had some
effect on the quantification of pulsatility. With the exception of pulse pressure, all indices
appeared to have some impact by flow and pressure. EEP had strong linear correlation
with MAP (R2 = 0.8). This correlation was explained because hemodynamic energy (and
pulsatility based on hemodynamic energy levels) increased with higher flow and pressure
levels. Endothelial shear stress appeared to have a slight proportional relationship with
flow and pressure, but with poor correlation. Shear stress, a function of flow rate, would
be theoretically related to mean flow rate, but this shear stress is calculated from peak
flow rates which can vary at a given mean flow. PIfreq and SHE seem to increase as
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pressure and flow levels drop; these correlations are weak as well. A drop in mean aortic
flow in the presence of maintained flow frequency from the cup could drive the PIfreq up
during DMVA support at lower outputs. MAP decreased more quickly than the
hemodynamic energy dropped at low outputs causing DMVA’s rise in SHE. Because
only EEP had a strong correlation with MAP, EEP could be normalized by it. No other
metric could be normalized by flow or pressure.
For this comparison of pulsatility between DMVA and the beating heart, support at
normal cardiac outputs is the only condition that is valuable. DMVA at lower cardiac
outputs was due to improper settings in the device such as wrong cup size or wrong
pressure input, and these results disregarded. Adequate consideration of DMVA’s ability
to restore arterial pulsatility required attention to DMVA at normal physiologic outputs.
Of ultimate importance is that pulsatility was restored by the DMVA support to the
baseline physiologic levels and equivalent to or higher than that of the unsupported
beating heart at the same output. Only EEP and PowIdx had significance between DMVA
and beating heart because DMVA was at a lower cardiac output and possessed less
energy than the hyper-dynamic condition. But with terms of relative pulsatility such as
EEP/MAP and SHE, DMVA was equivalent to the pre-experiment baseline. Since the
heart is fibrillating during support, the DMVA cup provided essentially all the heart
function. Significance in arterial pulsatility between DMVA support and the beating heart
at the same cardiac output occurred when the heart was weakened and essentially in a
failure state following defibrillation.
Future studies on DMVA might consider redefining pulsatility based on power which
is the product of flow and pressure so to truly represent both elements. Pulsatility has yet
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to be actually quantified by both flow and pressure, since its indices essentially become
pressure or dimensionless from the conventional metrics. A power analysis would be
more robust and better account for the presents of pulsatility in the arterial flow and
pressure. Perhaps simply a root-mean-square of the instantaneous power could represent
the pulsatility, or even a more complex calculation of power such as those already
attempted in literature could better quantify pulsatility. However, to effectively compare
pulsatile flow, a better means of quantifying pulsatility than the conventional measures is
essential.
Other possible studies on DMVA could consider pulsatility in other ways. DMVA
supports both ventricles simultaneous from the cup; the pulmonary pulsatility likely is
effected by the device. Effects to pulmonary pulsatility may be of interest. And while my
current study has analyzed pulsatility of DMVA support during fibrillation, the pulsatility
may respond differently to DMVA’s interaction with a weakly beating heart. These sorts
of studies on DMVA’s affect to pulsatility should be considered.
The absence of natural functionality in the fibrillating heart provided an ideal model to
determine the impact of DMVA mechanics since the heart’s function came almost
entirely from the device. DCC devices have been considered advantageous in generating
physiologic pulsatile flow compared to many blood pumps. By definition, DCC devices
better replicate pump dynamics than blood-contacting devices because DCC is directly
pumping by myocardial contractility. However, it was not known whether this external
pumping motion truly generated arterial pulsatile flow equivalent to the intrinsic
pulsatility from the heart’s contractility. This study suggests that external compression of
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the heart by DMVA can indeed restore pulsatility to physiologic levels; a summary of
results is in Table 4.
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Table 4. Summary of results. Pulsatile characteristics in arterial blood flow were restored
by DMVA support for the fibrillating heart. All pulsatile metrics from DMVA support
were equivalent to or higher than those of the unsupported beating heart at the same
cardiac output. DMVA’s arterial pulsatility was equivalent to that of the pre-experiment
baseline heart in all terms except EEP and PowIdx at which the baseline had a higher
cardiac output and thus higher hemodynamic energy levels. However, in terms of relative
hemodynamic energy such as EEP/MAP or SHE, pulsatility from DMVA was equivalent
to the pre-experiment baseline beating heart.
Measures of Pulsatility
Experimental
Condition

Sample
Size

CO
(L/min)

MAP
(mmHg)

PP
(mmHg)

Freq
PI

EEP
(mmHg)

EEP/MAP

SHE
(mmHg)

PowIdx
(W)

Baseline Beating
Heart

35

3.08
± 0.06

94.20
± 4.03

68.95
± 4.79

0.72
± 0.05

112.35
± 4.21

1.22
± 0.02

18.15
± 1.09

0.74
± 0.03

DMVA Support for
Fibrillating Heart

47

2.71
± 0.05*

77.33
± 4.24*

70.56
± 4.25

0.82
± 0.04

96.23
± 4.26*

1.26
± 0.02

18.94
± 1.15

0.53
± 0.03*

Unsupported
Failing Heart

87

2.70
± .05*

83.60
± 3.63*

39.71
± 3.44*^

0.68
± 0.04^

96.18
± 3.79*

1.16
± 0.02*^

12.59
± 0.98*^

0.53
± 0.03*

Values expressed as Mean ± SEM; * p<0.05 vs Baseline; ^ p<0.05 vs DMVA
CO = cardiac output; MAP = mean arterial pressure; PP = pulse pressure; Freq PI = frequency pulsatility index;
EEP = energy equivalent pressure; SHE = surplus hemodynamic energy; PowIdx = power index
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V. CONCLUSION
This study compared pulsatility in arterial blood flow between DMVA support of the
fibrillating heart and the naturally beating heart and suggested the equivalency of arterial
flow pulsatility between DMVA and the naturally beating heart. In the present state of
cardiac support devices in which most devices generate nonpulsatile flow by convention,
DMVA provides non-blood contacting pulsatile flow support. Pulsatility was quantified
based on pressure dynamics, frequency harmonics, and hemodynamic energy and was
shown to be similar between DMVA support and the pre-experiment beating heart. The
levels of pulsatility from DMVA support were similar to those of the post-arrest beating
heart at the same cardiac output. Based on lack of significance, this study suggests that
DMVA restores pulsatile characteristics in arterial flow in a fibrillating heart to that of
the native beating heart.
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